)
Overview
<ul>
<li>Canada biopharma firm’s Q1 net loss widened to $2.2 mln, driven by higher expenses</li>
<li>Operating expenses rose to $2.3 mln due to increased R&amp;D and admin costs</li>
</ul>
Outlook
<ul>
<li>Company anticipates recruitment for vitiligo study to begin midyear 2026</li>
<li>Edesa exploring accelerated commercialization pathways for paridiprubart</li>
<li>Company plans to establish investigational sites across multiple jurisdictions</li>
</ul>
Result Drivers
<ul>
<li>VITILIGO STUDY PREPARATION - Increased R&amp;D expenses due to manufacturing and preparations for Phase 2 study of EB06 in vitiligo patients</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q1 EPS -$0.28</h3>
Q1 Net -$2.2
Income mln
Q1 $2.3 mln
Operatin
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Edesa Biotech Inc is $9.00, about 804.5% above its February 12 closing price of $1.00</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

IBBQ

SBIO

EDSA

LABD

Canada's Edesa Biotech reported a Q1 net loss of $2.2 million, an increase attributed to higher operating expenses of $2.3 million driven by R&D and administrative costs. The company plans to start recruitment for a vitiligo study in mid-2026 and is exploring commercialization pathways for paridiprubart. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $9.00, significantly above its recent closing price of $1.00.

Canada's Edesa Biotech Q1 net loss widens